RecruitingPhase 1NCT06479811

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Studying Hereditary pheochromocytoma-paraganglioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Frank I Lin, M.D.
National Cancer Institute (NCI)
Intervention
68Ga-DOTATATE(drug)
Enrollment
120 target
Eligibility
18-120 years · All sexes
Timeline
20252032

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06479811 on ClinicalTrials.gov

Other trials for Hereditary pheochromocytoma-paraganglioma

Additional recruiting or active studies for the same condition.

See all trials for Hereditary pheochromocytoma-paraganglioma

← Back to all trials